CoChat

Retroviral DNA Integration: Viral and Cellular Determinants of Target-Site Selection

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Retroviruses differ in their preferences for sites for viral DNA integration in the chromosomes of infected cells. Human immunodeficiency virus (HIV) integrates preferentially within active transcription units, whereas murine leukemia virus (MLV) integrates preferentially near transcription start sites and CpG islands. We investigated the viral determinants of integration-site selection using HIV chimeras with MLV genes substituted for their HIV counterparts. We found that transferring the MLV integrase (IN) coding region into HIV (to make HIVmIN) caused the hybrid to integrate with a specificity close to that of MLV. Addition of MLV gag (to make HIVmGagmIN) further increased the similarity of target-site selection to that of MLV. A chimeric virus with MLV Gag only (HIVmGag) displayed targeting preferences different from that of both HIV and MLV, further implicating Gag proteins in targeting as well as IN. We also report a genome-wide analysis indicating that MLV, but not HIV, favors integration near DNase I-hypersensitive sites (i.e., +/- 1 kb), and that HIVmIN and HIVmGagmIN also favored integration near these features. These findings reveal that IN is the principal viral determinant of integration specificity; they also reveal a new role for Gag-derived proteins, and strengthen models for integration targeting based on tethering of viral IN proteins to host proteins.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.0020060

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Retroviral DNA Integration and the Chimeric Viruses Used in This Study (A) The DNA breaking and joining reactions mediating integration. Gray ovals represent integrase monomers, thick red lines represent viral DNA, black lines represent target DNA, and dots represent 5′ ends. (1) Linear blunt-ended viral cDNA is bound by integrase as part of the preintegration complex. (2) Integrase removes two nucleotides from the 3′ ends of the viral DNA, exposing recessed 3′ hydroxyl groups. (3) IN joins the recessed 3′ ends of viral DNA to the target DNA. (4) Unpairing of the target DNA between the joined ends of the viral DNA yields gaps in the target DNA. (5) DNA repair enzymes fill in the gaps. (6) The provirus is flanked by repeated segments of the target DNA. (B) Chimeric HIV derivatives containing segments of MLV. At the top is the HIV parent virus, with vpr and env inactivated and the puromycin resistance gene in place of nef. Following that are the chimeras, with substitutions of MLV gag gene segments (MA-, p12-, and CA-encoding regions) for HIV MA and CA, or substitution of MLV IN for HIV IN, or both [20,21]. The MLV genome (indicated by an asterisk) is shown for comparison. The MLV used in this study (MLVPuro) was an MLV-based vector (LPCX) encoding the puromycin resistance gene with Gag, Pol, and Env provided in trans. Although we refer to “Gag” in the text, we note that Gag is in fact a polyprotein which is cleaved into individual functional proteins by the action of the viral protease. (C) Target-sequence duplication lengths made by HIV, MLV, and the chimeric viruses. (D) Primary sequences at the site of integration for HIV, MLV, the chimeric viruses, and a previously published MLV dataset (MLV-Burgess). On the x-axis are the top strand positions surrounding the point of integration, which is represented by the blue arrow and line (between positions −1 and 0). For each dataset, the proportion of each base at a given location was divided by the proportion of that base in the matched random control set, such that a base with a y value >1 is present at an increased frequency, while a base with a y value <1 is present at a decreased frequency compared to random sites. A dashed red box surrounds the target sequence that is duplicated upon integration.
Figure 1 Retroviral DNA Integration and the Chimeric Viruses Used in This Study (A) The DNA breaking and joining reactions mediating integration. Gray ovals represent integrase monomers, thick red lines represent viral DNA, black lines represent target DNA, and dots represent 5′ ends. (1) Linear blunt-ended viral cDNA is bound by integrase as part of the preintegration complex. (2) Integrase removes two nucleotides from the 3′ ends of the viral DNA, exposing recessed 3′ hydroxyl groups. (3) IN joins the recessed 3′ ends of viral DNA to the target DNA. (4) Unpairing of the target DNA between the joined ends of the viral DNA yields gaps in the target DNA. (5) DNA repair enzymes fill in the gaps. (6) The provirus is flanked by repeated segments of the target DNA. (B) Chimeric HIV derivatives containing segments of MLV. At the top is the HIV parent virus, with vpr and env inactivated and the puromycin resistance gene in place of nef. Following that are the chimeras, with substitutions of MLV gag gene segments (MA-, p12-, and CA-encoding regions) for HIV MA and CA, or substitution of MLV IN for HIV IN, or both [20,21]. The MLV genome (indicated by an asterisk) is shown for comparison. The MLV used in this study (MLVPuro) was an MLV-based vector (LPCX) encoding the puromycin resistance gene with Gag, Pol, and Env provided in trans. Although we refer to “Gag” in the text, we note that Gag is in fact a polyprotein which is cleaved into individual functional proteins by the action of the viral protease. (C) Target-sequence duplication lengths made by HIV, MLV, and the chimeric viruses. (D) Primary sequences at the site of integration for HIV, MLV, the chimeric viruses, and a previously published MLV dataset (MLV-Burgess). On the x-axis are the top strand positions surrounding the point of integration, which is represented by the blue arrow and line (between positions −1 and 0). For each dataset, the proportion of each base at a given location was divided by the proportion of that base in the matched random control set, such that a base with a y value >1 is present at an increased frequency, while a base with a y value <1 is present at a decreased frequency compared to random sites. A dashed red box surrounds the target sequence that is duplicated upon integration.CC BY · PubMed Central
Figure 2 Positions of Retroviral Integration Sites on the Human Chromosomes The human chromosomes are shown numbered. Centromeric regions (which are mostly unsequenced) are shown in gray. Relative gene density is indicated in the top bar on each chromosome by the intensity of the cyan coloration. Integration-site datasets (lower bars) are color-coded as indicated. Sites of integration near transcription start sites (within ± 5 kb), CpG islands (within ± 1 kb of a CpG midpoint), or 2 DNase I cleavage sites are shown as red dashes; other sites are black.
Figure 2 Positions of Retroviral Integration Sites on the Human Chromosomes The human chromosomes are shown numbered. Centromeric regions (which are mostly unsequenced) are shown in gray. Relative gene density is indicated in the top bar on each chromosome by the intensity of the cyan coloration. Integration-site datasets (lower bars) are color-coded as indicated. Sites of integration near transcription start sites (within ± 5 kb), CpG islands (within ± 1 kb of a CpG midpoint), or 2 DNase I cleavage sites are shown as red dashes; other sites are black.CC BY · PubMed Central
Figure 3 Frequency of Integration near Transcription Start Sites, CpG Islands, and DNase I Cleavage Sites, Illustrating the Contribution of MLV IN to Specificity (A and B) The percentage of integration sites (per kb) within each interval is shown for (A) transcription start sites, and (B) CpG islands. (C) DNase I cleavage sites, For each dataset, the proportion of integration sites found within ± 1 kb of two DNase I cleavage sites was divided by the proportion in the matched random control set. The dotted line represents the expected bar height if the observed data did not differ from the random control set. L1 is displayed as the ratio over an unmatched random set. Three asterisks denote p < 0.0001 by chi-square comparison to random sites. Single asterisk denotes p = 0.0396.
Figure 3 Frequency of Integration near Transcription Start Sites, CpG Islands, and DNase I Cleavage Sites, Illustrating the Contribution of MLV IN to Specificity (A and B) The percentage of integration sites (per kb) within each interval is shown for (A) transcription start sites, and (B) CpG islands. (C) DNase I cleavage sites, For each dataset, the proportion of integration sites found within ± 1 kb of two DNase I cleavage sites was divided by the proportion in the matched random control set. The dotted line represents the expected bar height if the observed data did not differ from the random control set. L1 is displayed as the ratio over an unmatched random set. Three asterisks denote p < 0.0001 by chi-square comparison to random sites. Single asterisk denotes p = 0.0396.CC BY · PubMed Central
Figure 4 Diagram of the Relationship of Transcription-Factor Binding Sites Enriched in the MLVPuro, MLV-Burgess, HIVmIN, and HIVmGagmIN Integration-Site Datasets The genomic sequences within 1 kb of each integration site were used for analysis. Ten matched random-control integration sites were compared to each experimental integration site. The cut-off value for over-representation was 2.0-fold. All comparisons achieved p ≤ 0.001. The number of enriched transcription-factor binding sites in each dataset is shown with the number of factors unique to each in parentheses. The edge labels show the number of commonly enriched sites between pairs of datasets.
Figure 4 Diagram of the Relationship of Transcription-Factor Binding Sites Enriched in the MLVPuro, MLV-Burgess, HIVmIN, and HIVmGagmIN Integration-Site Datasets The genomic sequences within 1 kb of each integration site were used for analysis. Ten matched random-control integration sites were compared to each experimental integration site. The cut-off value for over-representation was 2.0-fold. All comparisons achieved p ≤ 0.001. The number of enriched transcription-factor binding sites in each dataset is shown with the number of factors unique to each in parentheses. The edge labels show the number of commonly enriched sites between pairs of datasets.CC BY · PubMed Central
Figure 5 Effects of Gag Proteins on Integration Targeting (A) Clustering by the machine learning algorithm RandomForest, illustrating an influence of Gag determinants as well as IN. For a detailed description of the method, see Protocol S3. (B) An analysis of the G/C percentage at integration sites.
Figure 5 Effects of Gag Proteins on Integration Targeting (A) Clustering by the machine learning algorithm RandomForest, illustrating an influence of Gag determinants as well as IN. For a detailed description of the method, see Protocol S3. (B) An analysis of the G/C percentage at integration sites.CC BY · PubMed Central
Figure 6 Effects of Selection for Provirus Gene Expression on the Distribution of Integration Sites (A) Frequencies of integration in RefSeq genes in the HIV-Burgess and HIVPuro datasets. (B) Comparison of the relative frequency of integration in the HIV-Burgess and HIVPuro datasets as a function of transcriptional intensity. The proportion of integration sites from each dataset in regions of varying transcriptional intensity was plotted increasing from left to right along the x-axis (in groups divided according to deciles of density). For “expressed genes” in this plot, we counted the number of genes whose expression level in HeLa cells was in the upper 1/8th of genes assayed on the HG-U133A microarray. The p-value given is the result of fitting a cubic polynomial to the expressed gene-density values. (C) Frequencies of integration in RefSeq genes in the MLV-Burgess and MLVPuro datasets. (D) Comparison of the relative frequency of integration in the MLV-Burgess and MLVPuro datasets as a function of transcriptional intensity. See Protocols S4 and S5 for details and additional plots.
Figure 6 Effects of Selection for Provirus Gene Expression on the Distribution of Integration Sites (A) Frequencies of integration in RefSeq genes in the HIV-Burgess and HIVPuro datasets. (B) Comparison of the relative frequency of integration in the HIV-Burgess and HIVPuro datasets as a function of transcriptional intensity. The proportion of integration sites from each dataset in regions of varying transcriptional intensity was plotted increasing from left to right along the x-axis (in groups divided according to deciles of density). For “expressed genes” in this plot, we counted the number of genes whose expression level in HeLa cells was in the upper 1/8th of genes assayed on the HG-U133A microarray. The p-value given is the result of fitting a cubic polynomial to the expressed gene-density values. (C) Frequencies of integration in RefSeq genes in the MLV-Burgess and MLVPuro datasets. (D) Comparison of the relative frequency of integration in the MLV-Burgess and MLVPuro datasets as a function of transcriptional intensity. See Protocols S4 and S5 for details and additional plots.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

Items 101–200 of 415

Metadata

Authors
Lewinski, M. K., Yamashita, M., Emerman, M., Ciuffi, A., Marshall, H., Crawford, G., Collins, F., Shinn, P., Leipzig, J., Hannenhalli, S., Berry, C. C., Ecker, J. R., & Bushman, F. D.
Affiliations
  • Salk Institute for Biological Studies (US)
  • Fred Hutch Cancer Center (US)
  • University of Pennsylvania (US)
  • National Institutes of Health (US)
  • University of California San Diego (US)
Corresponding author
Bushman, Frederic D
Venue
PLoS Pathogens
Published
2006-06-23
Volume
2
Issue
6
Pages
e60
ISSN
  • 1553-7366 (ISSN-L)
  • 1553-7374
OpenAlex
W1980869599
Cited by
364
References
46
Citations by year
2026: 3 · 2025: 8 · 2024: 3 · 2023: 5 · 2022: 16 · 2021: 5 · 2020: 9 · 2019: 11 · 2018: 7 · 2017: 18 · 2016: 21 · 2015: 15 · 2014: 26 · 2013: 25 · 2012: 32
FWCI
10.28
Type
journal article
Language
en
Open access
Locations
  • PLoS Pathogens (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • James B. Pendleton Charitable Trust
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases (R37AI030927, AI30927, R56AI030927, AI52845, AI 34786, R01AI034786, R01AI030927, R01AI052845)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords
retroviral integration, target site selection, HIV, murine leukemia virus, integrase, Gag protein, chimeric viruses, DNase I hypersensitive sites, CpG islands, transcription start sites, host-virus interaction
MeSH terms
Attachment Sites, Microbiological, Binding Sites, Chimera, Cloning, Molecular, Deoxyribonuclease I, DNA, Viral, Glycosaminoglycans, HeLa Cells, HIV, Humans, Leukemia Virus, Murine, Puromycin, Retroviridae, Transcription Factors, Transduction, Genetic, Virus Integration, Gene Transfer Techniques, CpG Islands, Integrases, Transcription Initiation Site

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.